Induction of cytochrome P450 (P450) activity in the clinic can result in therapeutic failure such as tissue rejection in transplant patients or unwanted pregnancy, among others. CYP3A4 is by far the most abundant isoform and is responsible for the majority of P450-related metabolism of all marketed drugs. However, it is of importance to understand the significance of induction mediated through other P450 enzymes. The objective of this investigation was to evaluate several known inducers in vitro using cryopreserved human hepatocytes, with the aim of assessing the relevant induction of CYP3A4, CYP2B6, CYP2C9, CYP2C19, and CYP3A5, based on mRNA expression. CYP3A4 induction was also assessed based on enzymatic activity in three different lots to investigate whether mRNA expression data have any advantages over enzymatic activity. In general, the mRNA fold-induction data results were more sensitive compared with activity data, and more informative in cases in which the drug is also a P450 inhibitor. The induction of transcription of other drug-metabolizing enzymes including CYP2B6 and CYP2C enzymes occurred every time that CYP3A4 mRNA levels increased, but to a lesser extent, indicating that measurement of CYP3A4 mRNA is a sensitive marker for the induction of these other enzymes. This was the case even for enzymes and inducers that are known to also act via the constitutive androstane receptor pathway. Finally, the utility of in vitro induction measurements in the identification of clinically meaningful inducers was tested by using two simple binary classification approaches: 1) fold-induction versus vehicle control and 2) induction response relative to rifampin. The best classification was observed when the cutoff criteria based on fold induction relative to the vehicle control, using mRNA data are used.
Introduction
The induction of cytochrome P450 (P450) enzymes can have clinical significance. The expression of the genes for these enzymes is inducible by numerous xenobiotics, resulting in altered drug metabolism and drug-drug interactions (DDIs). DDIs caused by enzyme induction could lead to loss of efficacy and/or increased toxicity via increased formation of reactive metabolites. PXR belongs to the nuclear receptor superfamily of ligand-activated transcription factors that includes vitamin D receptor (NR1I1), the constitutive androstane receptor (CAR; NR1I3), peroxisome proliferator-activated receptor (NR1C), and others (Germain et al., 2006) . Members of this NR1 subfamily of nuclear receptors typically function as heterodimers with the retinoid X receptor (RXR; NR2B1). In the unactivated state, the PXR/RXR heterodimers are thought to be retained in the cytoplasm, bound to heat shock proteins and/or various chaperone proteins (Squires et al., 2004) . Upon ligand binding, PXR/RXR translocates to the nucleus, binds DNA in the 5Ј-regulatory region of target genes, and interacts with various coregulatory proteins, thereby effecting gene transcription (Stanley et al., 2006) . Like the closely related receptor PXR, CAR exists as a heterodimer with RXR. Once in the nucleus, the CAR/RXR heterodimer is constitutively active; therefore, the translocation event is essentially a receptor activation event. CAR, like PXR, mediated the induction of numerous additional drug-metabolizing enzymes, including phase II enzymes and transporters, such as glutathione transferase A2, multidrug resistance 1, and UDPglucuronosyltransferase 1A1 (Maglich et al., 2002 (Maglich et al., , 2003 . In addition, it was recognized that many of the ligands that activate PXR can also activate CAR and that there is overlap in the target genes of these two receptors (Moore and Kliewer, 2000; Maglich et al., 2002; Wei et al., 2002) . Cytochrome P450 enzymes are regulated by both the PXR and CAR pathways. The nuclear receptor CAR is activated by fewer compounds than PXR but is responsible for regulating similar target genes such as CYP3A4 and CYP2B6. Most drugs that induce CYP3A levels are believed to do so primarily via PXR activation; however, there is overlap in activation with CAR in the sets of target genes that are expressed (e.g., CYP2B, CYP3A, and CYP2C). This explains the overlapping P450 induction patterns that exist; for example, rifampin induces CYP2B6, CYP2C9, and CYP3A4 genes in humans.
The CYP3A subfamily is involved in the oxidation of the largest range of substrates of all the P450s and is mostly found in the liver. CYP3A4 is by far the most abundant P450 isoform, constituting 30% of the P450 liver enzyme total in humans; it is also substantially expressed in the intestine and plays a dominant role in drug clearance, which is responsible for approximately 60% of P450-mediated metabolism of all marketed drugs (Frye, 2004) . Thus, induction of CYP3A4 represents a serious issue in pharmacotherapy. Two major forms of CYP3A are expressed in adult human tissues: CYP3A4 and CYP3A5. Whereas the former is found in the liver and small intestine of most individuals, CYP3A5 is polymorphically expressed in the liver and other organs (Lin et al., 2002) . Such polymorphisms contribute to interpatient variation and may affect the clinical efficacy and safe doses of a given drug.
The importance of CYP2B6 in drug metabolism has gained prominence recently. However, only a small proportion of drugs (estimated to be approximately 8%) show some metabolism by CYP2B6 (Nolan et al., 2006) , such as bupropion, methadone, efavirenz, ketamine, and tamoxifen (Kharasch et al., 2008) .
The human CYP2C gene subfamily of cytochrome P450 enzymes, composed of at least four distinct genes, namely CYP2C8, CYP2C9, CYP2C18, and CYP2C19, is responsible for the metabolism of approximately 20% of all clinically prescribed therapeutic agents (Ferguson et al., 2005) . The CYP2C subfamily constitutes approximately 30 to 40% of hepatic P450 content, with CYP2C9 being the most highly expressed and CYP2C19 having the lowest hepatic expression levels. CYP2C9 is responsible for metabolizing several anti-inflammatory drugs such as celecoxib, ibuprofen, naproxen, and tenoxicam. CYP2B6, CYP2C9, and CYP2C19 are also induced by rifampin and some of the other classic CYP3A4 inducers.
The objective of this investigation was to evaluate several known literature inducers with varying levels of PXR/CAR contributions, with the aim of assessing the relevant induction potency of CYP3A4, CYP2B6, CYP2C9, CYP2C19, and CYP3A5 in vitro, based on mRNA expression. CYP3A4 induction was assessed also based on enzymatic activity to investigate whether mRNA expression data have any advantages over enzymatic activity. Finally, an assessment of previously proposed criteria for the use of in vitro induction data to classify compounds as clinically relevant inducers (Bjornsson et al., 2003) was tested against other binary classification criteria using the data described in this report and clinical induction data gathered from the scientific literature.
Materials and Methods
Cell Culture and Cryopreserved Human Hepatocytes. Leflunomide, roxithromycin, ranitidine, fluoxetine, acetyl acetic acid, fluvoxamine, flumazenil, rosiglitazone, omeprazole, dexamethasone, carbamazepine, efavirenz, modafinil, nafcillin, nifedipine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, topiramate, troglitazone, Dulbecco's phosphate-buffered saline, and DMSO were purchased from Sigma-Aldrich (St. Louis, MO). Ritonavir, fluconazole, gatifloxacin, nitrendipine, pioglitazone, and nifedipine were obtained from Sequoia Research Products, Ltd. (Pangbourne, UK). Aprepitant, avasimibe, pioglitazone, and pleconaril were produced at Pfizer Global Research and Development (Groton, CT). All assay treatments were as previously published (Fahmi et al., 2008a,b) . Three lots of human cryopreserved hepatocytes were used in this study, lots Hu8020 and Hu4026 (CellzDirect, Durham, NC) and lot RCP (Celsis In Vitro Technologies, Chicago, IL).
Treatment of Cryopreserved Human Hepatocytes. Human cryopreserved hepatocytes were thawed in hepatocyte thawing medium and were seeded in collagen I-precoated 24-well plates, each well having a cell density of 3.5 to 4.2 ϫ 10 5 viable cells in 0.5 ml of hepatocyte plating medium. Viability as determined by trypan blue exclusion was 85% or better for this study. The cells were maintained at 37°C in a humidified incubator with 90% atmospheric air and 5% CO 2 . Cells were incubated for 24 h before being treated with compounds. All drugs were dissolved in DMSO and then added to the culture medium (final DMSO concentration, 0.1%). Incubation medium containing 0.1% DMSO served as the vehicle control. After daily treatment for 3 days, the medium was removed, and the cells were washed with saline. Enzyme activity and mRNA levels were then measured as described below.
Testosterone 6␤-Hydroxylation Measurement. After the incubation phase of the experiment, the medium containing controls or test article was removed, the cells were washed with saline, and fresh medium was added to all wells for a 30-min wash. After removal of the wash medium, 200 M testosterone in phosphate-buffered saline was added to each well, and the plate was returned to the incubator. After incubation for 30 min, 200 l of the medium from each well was removed and filtered using a Millipore Multiscreen HA filter plate to remove protein. Samples were directly injected onto the high-performance liquid chromatograph. Testosterone metabolites were analyzed by high-performance liquid chromatography with UV detection at 254 nm (Fahmi et al., 2008a) . Concentrations of 6␤-hydroxytestosterone were extrapolated via a standard curve (50 -0.1 M) also prepared in phosphatebuffered saline.
CYP3A4, CYP2B6, CYP3A5, CYP2C9, and CYP2C19 mRNA Preparation and Analysis. The assay was performed according to a previously published method (Fahmi et al., 2008a) . The gene-specific primer/probe sets used were as follows: for CYP3A4 target cDNA, Hs00604506_m1; for CYP2B6 target cDNA, Hs03044636_m1; for CYP2C9 target cDNA, Hs00426397_m1; for CYP2C19 target cDNA, Hs00426380_m1; for CYP3A5 target cDNA, Hs01070905_m1; and for glyceraldehyde-3-phosphate dehydrogenase endogenous control, Hs99999905_m1.
Assay Selectivity and Specificity. Sensitivity and specificity are statistical measures of the performance of a binary classification test and are measured as shown below. Sensitivity measures the proportion of actual positives that are correctly identified as such. Specificity measures the proportion of negatives that are correctly identified. 
Results
Comparison of Induction of CYP3A4 mRNA-and CYP3A4-Catalyzed Testosterone 6␤-Hydroxylase Activity. Three lots of cryopreserved human hepatocytes were challenged with 20 known clinical inducers and 15 clinical noninducers, and both CYP3A4 mRNA levels and CYP3A4 catalytic activities were measured (Tables 1 and 2) ; the maximum fold induction observed is showing for both enzymatic activity and mRNA. The maximum fold increases (E max ) in mRNA levels, relative to those in vehicle-treated hepatocytes, were almost always greater than the maximum fold increases in activity, indicating that mRNA is a more sensitive marker for induction. The differences in fold increase in mRNA relative to activity were 6.4 Ϯ 5.4, 4.3 Ϯ 4.1, and 3.1 Ϯ 3.6 for lots Hu4026, RCP, and Hu8020, respectively. The most noteworthy differences were observed for nevirapine, aprepitant, and nafcillin. Some differences in mRNA versus activity were even observed between the lots. For example, topiramate showed a marked difference in response between mRNA and activity in two lots, but in the third lot the increase in activity approached the same value measured for mRNA.
Comparison of the Measurement of Increase in CYP3A4 mRNA with mRNA Increases for Other Inducible Drug-Metabolizing Enzymes. The increases in mRNA observed for five drugmetabolizing enzymes (CYP3A4, 3A5, 2B6, 2C9, and 2C19) upon treatment with 20 different compounds were compared (Table 3) . In every instance, the increase in CYP3A4 mRNA was greater than the mRNA increases for all other enzymes. In general, the mRNA for CYP2B6 increased to the next greatest extent. The ratios of increases in CYP3A4 mRNA to CYP2B6 were lowest for phenobarbital, phenytoin, and troglitazone. CYP3A4 mRNA levels increased, on aver- Clinical Relevance of Simple Indices of In Vitro Induction Response: E max and Comparisons to Rifampin. The in vitro induction data gathered for this set of drugs were compared with drug interaction data gathered from the scientific literature. Whereas previous reports have described methods whereby in vitro induction data can be used to attempt quantitative prediction of induction response in vivo (Persson et al., 2006; Ripp et al., 2006; Sinz et al., 2006; Fahmi et al., 2008a Fahmi et al., ,b, 2009 Hariparsad et al., 2008; Kanebratt and Andersson, 2008; Shou et al., 2008) , in this case simple bimodal categorizations were used to define inducer versus noninducer. For clinical data, a drug was considered an inducer if the exposure to the clinical marker probes (e.g., midazolam, simvastatin, and others) decreased by 20% or more upon treatment with multiple doses of the inducer. For the in vitro data, two categorizations were used to assign a drug as an inducer or noninducer: 1) a cutoff of maximum induction achieving 40 and 20% of the effect of rifampin (at 25 M) as assessed by measurement of CYP3A4 catalytic activity (Bjornsson et al., 2003) and CYP3A4 mRNA (Tables 4 and 5) ; and 2) a cutoff of a mean fold maximum increase in CYP3A4 mRNA (4-fold) and enzymatic activity (2-fold) (Table 6 ) from three human hepatocyte lots. The fidelity of these cutoff parameters is summarized in Tables 4, 5 (Table 4) , the rates of correct categorization were 55, 46, and 58% for lots Hu4026, RCP, and Hu8020, respectively. The rates of false-positives were 23, 27, and 31% and the rates of false-negatives were 60, 75, and 50% for lots Hu4026, RCP, and Hu8020, respectively. When the cutoff of maximum induction is lowered to 20% of the effect of rifampin, the rates of false-positives were 23, 33, and 38% and the rates of false-negatives were 55, 40, and 39% for lots Hu4026, RCP, and Hu8020, respectively. When the mRNA data were assessed based on the cutoff of maximum induction at 40% of the effect of rifampin, the rates of correct categorization were 61, 69, and 55% for lots Hu4026, RCP, and Hu8020, respectively. Rates of false-positives were 38, 33, and 38% and falsenegatives rates were 40, 30, and 50% for lots Hu4026, RCP, and Hu8020, respectively, indicating that this approach is probably not suitable to identify clinical inducers, especially because of the high rates of false-negatives. The same approach was investigated using a more conservative cutoff of 20% relative to the effect of rifampin and led to some improvement in detecting inducers based on mRNA (false-negatives rates were 30, 0, and 22% for lots Hu4026, RCP, and Hu8020, respectively) but no significant improvement based on enzymatic activity data (55, 40, and 39% for lots Hu4026, RCP, and Hu8020, respectively).
Based on enzymatic activity of 2-fold, the rates of correct categorization (Table 6) were 69, 74, and 81% for lots Hu4026, RCP, and Hu8020, respectively. The rates of false-positives were 27, 27, and 36% and the rates of false-negatives were 35, 25, and 6% for lots Hu4026, RCP, and Hu8020, respectively. When the mRNA data were assessed using a mean cutoff of 4-fold increase, the rates of correct categorization were 79, 83, and 81% for lots Hu4026, RCP, and Hu8020, respectively. Rates of false-positives were 46, 40, 46, and false-negatives rates were 5, 0, and 0% for lots Hu4026, RCP, and 
TABLE 4

Truth tables for categorizing clinically meaningful inducers (20 inducers and 15 noninducers) using in vitro induction data (lots Hu4026, RCP, and Hu8020) and cutoff values of 40% of rifampin response based on CYP3A4 mRNA (A, C, and E, for lots Hu4026, RCP, and Hu8020) or based on enzymatic activity (B, D, and F)
TABLE 5
Truth tables for categorizing clinically meaningful inducers (20 inducers and 15 noninducers) using in vitro induction data (lots Hu4026, RCP, and Hu8020) and cutoff values of 20% of rifampin response based on CYP3A4 mRNA (A, C, and E for lots Hu4026, RCP, and Hu8020) or based on enzymatic activity (B, D, and F)
Hu8020, respectively. When in vitro induction data were used to inform a clinical DDI study strategy, the latter criteria offer the most conservative approach (i.e., may conduct clinical studies that come out as negative but will not miss any inducers). This conclusion is best illustrated in Table 7 , in which the specificity and sensitivity of the approach of using 4-fold induction as the cutoff value, based on mRNA, show 98% sensitivity but 69% selectivity.
Discussion
Induction of drug-metabolizing enzymes is an important mechanism underlying some drug-drug interactions. Increases in expression levels of important enzymes, such as CYP3A4, can cause increases in the intrinsic clearance of many drugs, resulting in decreases in their plasma concentrations and in some cases a loss of efficacy. Thus, it is important to be able to find agents capable of causing induction early in the drug research process to identify those compounds most prone to this activity and select alternate agents that will lack this activity. Several types of assays have been described for this purpose, such as PXR binding assays and reporter gene approaches using engineered systems (Sinz et al., 2006) . However, the use of human hepatocytes in testing for induction remains the most widely accepted approach for making in vitro assessments of induction, especially for informing clinical drug interaction study strategies and inclusion of data in drug registration dossiers and product labels. Previously, there were practical challenges with the use of human hepatocytes for induction studies due to inconsistent supplies of cells that yielded acceptable responses and no manner of conducting cross-compound comparison of large numbers of drugs in individual sources. With the recent achievement of hepatocyte cryopreservation techniques, these limitations have been overcome because reliable supplies of cells that can be thawed and used over periods of time are now available. Cells from individual donors can be tested for induction response using known positive control compounds and those providing the most robust responses can be selected for routine testing of new compounds.
To measure induction of drug-metabolizing enzymes in vitro, several endpoints can be chosen. Activation of PXR yields increases in transcription of several genes for drug-metabolizing enzymes and drug transporters, and these increases in mRNA result in increased biosynthesis of the corresponding proteins. Because they are under the control of this receptor, it might be expected that the levels of these various messages and proteins would behave similarly to each other. However, this is not necessarily the case. In some cases, the changes in transcription and activity may not run in parallel because the drug-activating PXR could also directly affect the activity of the protein. For example, some drugs can cause an increase in transcription of CYP3A4 and several other drug-metabolizing enzymes, yet also be mechanism-based inactivators of CYP3A4. Thus, if CYP3A4 activity were used as the marker for induction activity, an erroneous conclusion could be made that such a compound will not cause clinical induction, yet the other induced but noninactivated enzymes will still have increased expression and activity. To avoid such a pitfall, measurement of the activities or transcripts of all inducible drug-metabolizing enzymes and transporters could be individually measured. Alternately, a more streamlined approach would be to measure the increase in mRNA of one of the induced enzymes as a marker for PXR activation and induction potential. In this report, a comparison of the induction of CYP3A4 mRNA, CYP3A4 catalytic activity, and the transcription of four other PXR-regulated drugmetabolizing P450s were measured in three lots of cryopreserved human hepatocytes to better define the most sensitive marker (CYP3A4 mRNA) for detecting induction in vitro and determining how well that marker distinguishes clinically meaningful inducers from noninducers.
The data clearly show that measurement of CYP3A4 mRNA levels represents the most sensitive marker for detecting induction in human hepatocytes. Several compounds were shown to cause marked increases in CYP3A4 mRNA, whereas the increases in catalytic activity were much lower. For example, aprepitant caused 7.6-to 16-fold increases in CYP3A4 mRNA, but activity levels actually decreased. Truth tables for categorizing clinically meaningful inducers (20 inducers and 15 noninducers), using in vitro induction data (lots Hu4026, RCP, and Hu8020, respectively) and cutoff values of 4-fold increase in CYP3A4 based on CYP3A4 Based mRNA (a, c, and e for lots Hu4026, RCP, and Hu8020) or 2-fold increase in enzymatic activity (b, d, and f for lots Hu4026, RCP, and Hu8020) This finding suggests that aprepitant does induce expression of drugmetabolizing enzymes and that one might expect a clinical drug interaction between aprepitant and other drugs. In the clinic, aprepitant has been shown to cause a decrease in midazolam clearance but induction of ethinyl estradiol clearance [ (Majumdar et al., 2003) and (New Drug Application 021549 to the Food and Drug Administration)].
In addition, compared with mRNAs for other drug-metabolizing enzymes (CYP3A5, 2B6, 2C9, and 2C19), the mRNA for CYP3A4 increases more in all cases. This result suggests that if one measurement should be chosen for testing for induction, that measurement should be CYP3A4 mRNA. Genes for enzymes proposed to also be regulated by the CAR, such as CYP2B6 or CYP2C19, demonstrate increased transcription upon treatment with known CAR mechanism inducers such as phenobarbital and phenytoin. However, these inducers still caused an even greater increase in mRNA levels for CYP3A4, supporting the fact that just the measurement of CYP3A4 mRNA is adequate to determine the possibility that a compound will be an inducer. Thus, measurement of mRNA for these other drug-metabolizing enzymes should not be necessary to identify inducers, even if a compound were to only activate CAR.
Finally, the utility of in vitro induction measurements in the identification of clinically meaningful inducers was tested. As opposed to more sophisticated approaches for quantitatively predicting clinical drug interactions caused by induction (Persson et al., 2006; Ripp et al., 2006; Sinz et al., 2006; Fahmi et al., 2008a Fahmi et al., ,b, 2009 Hariparsad et al., 2008; Kanebratt and Andersson, 2008; Shou et al., 2008) , in this report a simple binary classification of inducers was attempted. Simpler approaches such as this are more amenable to early drug research efforts when hundreds of compounds must be assessed. In addition, an approach whereby a simple comparison of induction responses for new compounds with that of rifampin as a positive control had been previously proposed (Bjornsson et al., 2003 ; U.S. Food and Drug Administration, http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm072101.pdf). As with any pharmacological effect, an induction response will be dictated not only by the maximum possible effect but also by the relationship between the concentration in vivo and the intrinsic binding potency (Smith et al., 2007) . Thus, the use of single, high concentrations of test compounds in in vitro induction assays may yield a high rate of false-positive results, because test concentrations far exceed those that are achieved in vivo. Nevertheless, testing of this binary classification was attempted. The results demonstrate that there are high false-negative rates if the cutoff based on fold induction relative to the positive control is applied. The best classification was observed when mRNA data for which the cutoff (4-fold) is based on absolute fold induction (Table 6 ) relative to the vehicle control are used, as no false-negatives were observed in two of the three lots tested. However, terbinafine, which is a weak clinical inducer suggested by the observed decrease of midazolam exposure of 24.5%, was not identified as an in vitro inducer in one of the lots tested. This observation confirms the need to evaluate new chemical entities with three different human hepatocytes lots as recommended by the U.S. Food and Drug Administration (http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072101.pdf). It is also worth mentioning that notable differences were observed with the three human lots of hepatocytes used in this study. For example, lot RCP seemed to give rise to less false-positives based on mRNA with fold induction and the 20% cutoff criteria approaches.
Even though using the cutoff of 4-fold based on mRNA shows no false-negatives, there is a relatively high percentage of false-positive results (approximately 43%) (Table 7) , if absolute fold induction is considered regardless of the in vivo plasma concentration. Some of the clinical noninducers such as rosiglitazone, nifedipine, omeprazole, nitrendipine, pioglitazone, and fluvoxamine show induction in vitro (Table 2) . However, a drug such as rosiglitazone shows induction in vitro only at concentrations of 30 M and above, which far exceed the actual C max of 1.4 M (Fahmi et al., 2008a) . Another example is omeprazole, for which induction in vitro is observed at concentrations of 25 M and above, which far exceed the plasma concentration of 0.68 M. Therefore, it is crucial to design the in vitro induction study around expected in vivo plasma concentration.
In conclusion, the measurement of CYP3A4 mRNA as a marker for PXR-based induction serves as the most sensitive indicator for the potential for induction. This endpoint has the advantage over measurement of CYP3A4 activity in that compounds that activate PXR but also inhibit/inactivate CYP3A4 will not be missed. The induction of transcription of other drug-metabolizing enzymes including CYP2B6 and CYP2C occurred every time that CYP3A4 mRNA levels increased, albeit to a lesser extent, indicating that measurement of CYP3A4 mRNA is a sensitive marker for the induction of these other enzymes. This was the case even for enzymes and inducers that are known to also act via the CAR pathway. Although a binary approach to assignment of inducers versus noninducers from CYP3A4 mRNA tends to overpredict the frequency of clinically relevant inducers, this is probably due to the use of single, high concentrations that far exceed clinically relevant exposure levels.
